Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
Patel JD, Lee JW, Carbone DP, Wagner H, Shanker A, de Aquino MTP, Horn L, Johnson ML, Gerber DE, Liu JJ, Das MS, Al-Nsour MA, Dakhil CSR, Ramalingam S, Schiller JH. Patel JD, et al. Among authors: ramalingam s. Clin Lung Cancer. 2020 Nov;21(6):520-526. doi: 10.1016/j.cllc.2020.06.007. Epub 2020 Jun 12. Clin Lung Cancer. 2020. PMID: 32807654 Free PMC article. Clinical Trial.
CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
De Ruysscher D, Ramalingam S, Urbanic J, Gerber DE, Tan DSW, Cai J, Li A, Peters S. De Ruysscher D, et al. Among authors: ramalingam s. Clin Lung Cancer. 2022 May;23(3):e264-e268. doi: 10.1016/j.cllc.2021.07.005. Epub 2021 Jul 19. Clin Lung Cancer. 2022. PMID: 34489161 Free article. Clinical Trial.
Bevacizumab's Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC.
Varlotto JM, Wang Y, Sun Z, Wakelee HA, Ramalingam S, Schiller J. Varlotto JM, et al. Among authors: ramalingam s. JTO Clin Res Rep. 2022 Jan 10;3(3):100274. doi: 10.1016/j.jtocrr.2021.100274. eCollection 2022 Mar. JTO Clin Res Rep. 2022. PMID: 35281954 Free PMC article.
Multivariate analysis of survival, local control, and time to distant metastases in patients with unresectable non-small-cell lung carcinoma treated with 3-dimensional conformal radiation therapy with or without concurrent chemotherapy.
Wolski MJ, Bhatnagar A, Flickinger JC, Belani CP, Ramalingam S, Greenberger JS. Wolski MJ, et al. Among authors: ramalingam s. Clin Lung Cancer. 2005 Sep;7(2):100-6. doi: 10.3816/CLC.2005.n.024. Clin Lung Cancer. 2005. PMID: 16179096
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.
Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, Webb T, Harper H, Huberman M, Ramalingam S, Wong KK, Teofilovici F, Guo W, Shapiro GI. Socinski MA, et al. Among authors: ramalingam s. Clin Cancer Res. 2013 Jun 1;19(11):3068-77. doi: 10.1158/1078-0432.CCR-12-3381. Epub 2013 Apr 3. Clin Cancer Res. 2013. PMID: 23553849 Free PMC article. Clinical Trial.
A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181.
Varlotto JM, Sun Z, Ky B, Upshaw J, Fitzgerald TJ, Diehn M, Lovly C, Belani C, Oettel K, Masters G, Harkenrider M, Ross H, Ramalingam S, Pennell NA. Varlotto JM, et al. Among authors: ramalingam s. Clin Lung Cancer. 2022 Nov;23(7):547-560. doi: 10.1016/j.cllc.2022.06.005. Epub 2022 Jun 30. Clin Lung Cancer. 2022. PMID: 35882620 Review.
A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.
Osta BE, Carlisle J, Steuer C, Pakkala S, Leal T, Dhodapkar M, Liu Y, Chen Z, Owonikoko T, Ramalingam S. Osta BE, et al. Among authors: ramalingam s. Clin Lung Cancer. 2022 Nov;23(7):e400-e404. doi: 10.1016/j.cllc.2022.06.003. Epub 2022 Jun 22. Clin Lung Cancer. 2022. PMID: 35863963 Clinical Trial.
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial.
Lara PN Jr, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR. Lara PN Jr, et al. Among authors: ramalingam s. Clin Lung Cancer. 2011 Jan;12(1):33-7. doi: 10.3816/CLC.2011.n.004. Clin Lung Cancer. 2011. PMID: 21273177 Free PMC article. Clinical Trial.
1,126 results